IO Biotech

company

About

IO Biotech is a clinical-stage biotech company developing disruptive immune therapies for the treatment of cancer.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
€11M
Industries
Biotechnology,Health Care,Therapeutics
Founded date
Dec 23, 2014
Number Of Employee
1 - 10
Operating Status
Active

IO Biotech is a clinical stage biotech company developing disruptive immune therapies for the treatment of cancer. The pipeline of first-in-class immune modulating anti-cancer therapies is developed by a unique technology platform, T-win®, enabling the activation of T cells that are specific for immune-suppressive molecules. IO Biotech has a proven track record of progressing preclinical and clinical compounds. The two lead compounds targeting IDO and PD-L1 are in clinical development and several pipeline compounds are in pre-clinical phase.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€138M
IO Biotech has raised a total of €138M in funding over 2 rounds. Their latest funding was raised on Jan 13, 2021 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 13, 2021 Series B €127M 1 Detail
Jan 5, 2016 Series A €11M 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
IO Biotech is funded by 2 investors. Lundbeckfonden Emerge and Novo Nordisk are the most recent investors.
Investor Name Lead Investor Funding Round
Lundbeckfonden Emerge Series B
Novo Nordisk Series A